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Abstract
Objectives: Use electronic health records Autism Spectrum Disorder (ASD) to assess the comorbidity burden of ASD in
children and young adults.
Study Design: A retrospective prevalence study was performed using a distributed query system across three general
hospitals and one pediatric hospital. Over 14,000 individuals under age 35 with ASD were characterized by their co-
morbidities and conversely, the prevalence of ASD within these comorbidities was measured. The comorbidity prevalence of
the younger (Age,18 years) and older (Age 18–34 years) individuals with ASD was compared.
Results: 19.44% of ASD patients had epilepsy as compared to 2.19% in the overall hospital population (95% confidence
interval for difference in percentages 13.58–14.69%), 2.43% of ASD with schizophrenia vs. 0.24% in the hospital population
(95% CI 1.89–2.39%), inflammatory bowel disease (IBD) 0.83% vs. 0.54% (95% CI 0.13–0.43%), bowel disorders (without IBD)
11.74% vs. 4.5% (95% CI 5.72–6.68%), CNS/cranial anomalies 12.45% vs. 1.19% (95% CI 9.41–10.38%), diabetes mellitus type I
(DM1) 0.79% vs. 0.34% (95% CI 0.3–0.6%), muscular dystrophy 0.47% vs 0.05% (95% CI 0.26–0.49%), sleep disorders 1.12%
vs. 0.14% (95% CI 0.79–1.14%). Autoimmune disorders (excluding DM1 and IBD) were not significantly different at 0.67% vs.
0.68% (95% CI 20.14-0.13%). Three of the studied comorbidities increased significantly when comparing ages 0–17 vs 18–
34 with p,0.001: Schizophrenia (1.43% vs. 8.76%), diabetes mellitus type I (0.67% vs. 2.08%), IBD (0.68% vs. 1.99%) whereas
sleeping disorders, bowel disorders (without IBD) and epilepsy did not change significantly.
Conclusions: The comorbidities of ASD encompass disease states that are significantly overrepresented in ASD with respect
to even the patient populations of tertiary health centers. This burden of comorbidities goes well beyond those routinely
managed in developmental medicine centers and requires broad multidisciplinary management that payors and providers
will have to plan for.
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Introduction
Over the course of the last 30 years populations of children with
autism spectrum disorders have been studied to determine what
other non-psychiatric or neuro-cognitive clinical correlates or co-
morbidities might exist in this population [1,2,3,4,5,6,7,8,9,10].
Most of these studies have numbered fewer than 200 patients, thus
the estimation of prevalence for common co-morbid symptoms
and diseases were not accurate. Moreover low-prevalence
conditions could not be addressed at all. Nonetheless, given the
large numbers of children, possibly as many as 1% [11], with
ASD, the need for timely, comprehensive and accurate estimates
of these co-morbidities are all the more pressing. This is
particularly relevant as we enter an era of accountable care,
where baseline data for the cost of each segment of the patient
population will be obtained [12]. We have sought to leverage
recent developments in informatics technologies for distributed
queries across the electronic medical records (EMR) systems data
of multiple health care systems to provide a snapshot of this co-
morbidity landscape across four hospitals in the Boston area, one a
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pediatric services. In reporting on this study our motivation is first
to improve the quantification of the prior estimates of co-morbid
conditions such as sleep disorders [13], gastrointestinal complaints
and disorders [1,5,14,15], epilepsy [6], cranial anomalies [16],
muscular dystrophies [17,18,19,20] and schizophrenia [21] to
improve recognition and enable early intervention for these
morbidities that further challenge the management of individuals
with ASD. Conversely, we also wish to see, for selected co-
morbidities previously shown to have a higher prevalence of ASD,
what the healthcare system’s data estimate that prevalence to be
and how they change with age. Given the increased attention that
the care of children with ASD has obtained, we hope to stimulate
further formal assessment of the symptom and disease association
of ASD to allow policy makers and payors to take a full measure of
the burden of this common disorder beyond the methods afforded
by these EMR-based informatics techniques.
This study includes up to 14,381 individuals (but likely fewer as
reviewed in the Discussion) with ASD over a patient population of
2,393,778 below age 35 years (approximately 1 in 200 patients).
We employed a query system that does not require a centralized
database in order to respect the Health Insurance Portability and
Accountability Act (HIPAA), patient consent-to-care, and institu-
tional concerns. This query system entitled Shared Health
Resource Information Network (SHRINE) [22] was developed
as part of the Harvard Clinical Translational Science award and
also leverages the i2b2 National Center for Biomedical Computing
[23,24,25,26,27,28,29,30]
By its very nature, this study can only be exploratory and
suggestive. Understanding the degree to which changes in practice
or population stratification or referral bias may play in
determining the results requires further investigation of the
databases and records in each of the individual hospitals which
is both beyond the scope of this investigation and indeed is the
follow-on activity that tools such as SHRINE are designed to
stimulate. Also, this study uses ICD-9 codes (the controlled
vocabulary employed principally by healthcare providers to bill for
their services), of which some are clearly disease states while others
are codes representing symptom complexes. Without chart review
we cannot determine if, for example, a diagnosis is determined by
symptoms or by diagnostic tests. The ICD-9 codes are also coarse
grained and because there are often used for billing, they therefore
have potential for bias [31,32]. Additionally, the assignment of the
diagnostic codes will be in part determined by the nature of the
specialist seeing the patients which in turn will be driven by what
kinds of specialists are available at each hospital [33,34] Therefore,
we expect that the raw prevalence rates may differ from those
obtained in prior, smaller, and more fine-grained studies.
However, we also expect that there will be a close correspondence
in the directionality of increased/decreased co-occurrence of the
previously reported co-morbidities and ASD.
Notwithstanding, these limitations, the results presented here
summarize one of the largest populations analyzed for the co-
morbidity of a common disease that has a growing presence in
pediatric clinical practice.
Methods
Data Access
We used the Shared Health Research Informatics Network
(SHRINE) system [22] for extraction and analysis of whole
electronic record datasets from hospital systems equipped with a
variety of electronic health care records. This free software has
been deployed to over 60 academic health centers internationally.
SHRINE in its current implementation only returns aggregate
counts of patient populations meeting user-defined criteria based
on medications, laboratory data and diagnosis. The Institutional
Review Boards of Harvard Medical School, Beth Israel Deaconess
Medical Center, Children’s Hospital, Boston, and Partners
Healthcare Systems have reviewed this system and in the absence
of any identifying data and only aggregate counts (i.e. this
constitutes non-human subjects research per NIH and institutional
guidelines) have approved the research protocol and waived the
requirement for consent.
For the purpose of this study we only analyzed diagnoses
encoded in the ICD-9 system (see [35]) which is widely used in
healthcare and therefore can be used for replication/comparison
studies using less data-rich EMR systems available nationally [36].
For example, ASD in this study was defined to include the ICD-9
codes of autistic disorder, Asperger’s Syndrome and other
pervasive developmental disorders (i.e. ICD 9 codes 299.00,
299.01,299.10,299.11, 299.80, 299.81, 299.90, 299.91—see Table
S1). The study covers the period from 2001 to 2010.
Analysis
All data was analyzed using the base stats package of R. The
calculation of chi-square statistics, 95% confidence intervals on the
difference in proportions and p values were obtained from the
prop.test function.
SHRINE queries were composed to determine two sets of
fractions or conditional probabilities for those major co-morbid-
ities previously identified for ASD in individuals younger than 35
years of age. We further subcategorized the analyses into age
groups 0–17 and 18–34 to see how the co-morbidity prevalence
changed across those two age groups.
Results
The prevalence of symptoms and co-morbidities with ICD-9
codes corresponding to those diseases previously shown to be co-
morbid with ASD are shown in Table 1, and Table S2. Despite
the nature of the tools in this study, the estimates obtained are
consistent with those from prior studies. Within the group of
individuals with ASD, Epilepsy (ICD-9 Diagnosis Code 345.*, see
Table S1) was found to have prevalence of 19.4%, schizophrenia
2.4% (83 ICD-9 codes listed in Table S1), bowel disorders 11.7%
(112 ICD-9 Codes excluding those for inflammatory bowel
disease), inflammatory bowel disease 0.8% (ICD 9 555.* and
556.*), type 1 diabetes mellitus (subset of ICD9 250.* as in Table
S1) 0.8%, autoimmune disorders (which for the purpose of this
study, specifically excludes IBD and type 1 diabetes mellitus—See
Table S1) 0.7%, and CNS/head anomalies (80 ICD-9 codes)
12.4%. Sleep disorders (ICD9 307.4*) at 1.1% were much lower
than the prior estimates of 50% obtained in formal assessment of
children with ASD [13]. The prevalence of genetic disorders of
Fragile X Syndrome, Tuberous Sclerosis and Down Syndrome in
individuals with ASD prevalence of 0.5%, 0.8%, 0.9% is consistent
with prior studies finding that single gene disorders are responsible
for only small fractions of ASD even if collectively they might
exceed 20% [37]. Many other genetic syndromes could not be
assessed in this study because there was no corresponding ICD-9
code. For other EMR analysis projects we have successfully used
natural language processing (NLP) techniques across the clinical
notes for these ‘‘uncoded’’ syndromes. Such an approach, which
takes considerable time and effort to ensure the accuracy of each
phenotype [26,38], was beyond the scope of this investigation.
Also Figure 1is shown the prevalence of ASD in these same co-
morbidities where the aforementioned genetic disorders had ASD
Comorbidities of Autism Spectrum Disorder
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33224prevalences of 21%, 10.8%, and 3.1% respectively. Several other
co-morbidities had ASD prevalence of greater than 5% including
CNS anomalies (6.3%), epilepsy (5.3%), and schizophrenia (6.1%)
When prevalence of these co-morbidities in ASD were
compared to their prevalence in the general population captured
by this study (i.e. individuals with at least one inpatient or
outpatient visit to one of the four hospitals and therefore enriched
for diseases in the population less than 35 years of age—Figure 2),
all the above disorders were found to be at significantly higher
counts (Pearson’s chi-square, p,0.0001, 95% confidence intervals
shown in Table 2) except for autoimmune disorders (in ASD at
0.67% vs 0.68%, p,0.97). Even though the category of
autoimmune disorders was not significantly greater than the
general population, the autoimmune disorders excluded from this
category: type 1 diabetes mellitus and IBD were significantly
enriched. Also, bowel disorders were found to be significantly
increased, a point of some divergence in prior studies [39].
Although the prevalence of sleep disorders in ASD was found to be
lower than in prior studies, it nonetheless was approximately ten-
fold higher than the general (hospital) population, as was
schizophrenia. Muscular dystrophy was almost ten times more
prevalent in the ASD population than in the general population,
providing quantification absent in prior associations.
A question increasingly asked is how does the comorbidity
landscape of ASD change as children become young adults
[40,41]? Consequently we stratified the study population into two
Figure 1. Prevalence of co-morbidities of autism and prevalence of autism in these comorbidities. Shown here is the prevalence of co-
morbidities for individuals with autism (denoted as p(Dx}Autism) where Dx is the co-morbidity) and the reciprocal prevalence of autism given the co-
morbidity (i.e. p(Autism|Dx)). The prevalence is reported for patients younger than 35 years old. These results are consistent with prior studies and
also reinforce that monogenic disorders associated with autism individually only account for a small fraction of the disorder. It also reinforces that
autism is present in over 5% of the individuals evaluated for CNS anomalies, epilepsy, muscular dystrophy, schizophrenia, Fragile X Syndrome and
Tuberous Sclerosis.
doi:10.1371/journal.pone.0033224.g001
Table 1. Characteristics of the ASD population studied.
Characteristic Pediatric Hospital General Hospitals Sum
Total (All Patients, including ASD) 1246494 1147284 2393778
Male, ASD 7256 4153 11409
(Female+Male), ASD 9105 5276 14381
ASD, Schizophrenia 125 225 350
ASD, IBD 37 82 119
ASD, Bowel Disorders 880 808 1688
ASD, Type 1 DM 80 34 114
ASD, Autoimmune Disease 34 63 97
ASD, Sleep Disorders 113 48 161
ASD, Muscular Dystrophy 39 29 68
ASD, Fragile X Syndrome 47 28 75
ASD, Tuberous Sclerosis 31 72 103
ASD, Epilepsy 2235 561 2796
ASD, Down Syndrome 106 36 142
ASD, CNS/Cranial anomalies 900 890 1790
Counts given for patients in the pediatric and general hospital(s), and their sum. All counts are for patients under age 35.
doi:10.1371/journal.pone.0033224.t001
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not change significantly with age (using p,0.01 as threshold due
to multiple hypothesis testing): bowel disorders (11.63% to 12.97%
p,0.13), sleep disorders (1.25% to 0.41% p,0.05), and epilepsy
(19.17% to 21.45% p,0.05). In contrast DM1 (0.67 to 2.08%
p,4.5610
210), IBD (0.68% to1.99% p,9.7610
29) and schizo-
phrenia (1.43% to 8.76%, p,3.1610
279) were significantly
different, as in Figure 3. Excluding DM1 and IBD, the other
autoimmune disorders did not increase with age.
Although unsurprising, the male to female ratio in this large
sample was very close to 4:1 (see Table 1).
As an additional comparison, we conducted the parallel co-
morbidity study for fractures of the lower limb (FxLL) as
performed for ASD (see Table S3). All co-morbidities in ASD
were significantly higher than those for FxLL with two exceptions:
autoimmune disorders (excluding IBD and DM1 but including
rheumatological disorders such as rheumatoid arthritis and
systemic lupus erythematosus) and DM1. There are several
decades of documentation of the higher prevalence of FxLL in
both DM1 [42,43] and the rheumatological diseases (e.g Kim et al.
[44]).
Discussion
In this study across multiple health care systems with almost
15,000 patients with ASD, we have been able to corroborate, with
a few notable exceptions the co-morbidity findings of prior studies.
This study reinforces that burden of co-morbidity is substantial
Figure 2. Comorbidities in autism vs same morbidities in the general hospital population. All co-morbities have a significantly different
proportion in the ASD population (p,0.0001 by Chi-square) except for the autoimmune diseases (from which IBD and DM1 were excluded and are
shown separately on the chart) for which p,0.5. Several of the disorders (epilepsy, muscular dystrophy, schizophrenia, sleep disorders and CNS
anomalies have approximately an order of magnitude increased prevalence).
doi:10.1371/journal.pone.0033224.g002
Table 2. Proportions of morbidity in the subpopulation with ASD and that of the hospital population.
Disorder Prop in ASD
Prop in hosp. (95
th %
for D)
Prop in ASD, Age
0–17
Prop in hosp.
Age 0–17
Prop in ASD, Age
18–34
Prop in hosp.
Age 18–34
CNS/cranial anomalies 12.45% 1.19% (9.41–10.38%) 12.56% 2.08% 12.22% 0.44%
Epilepsy 19.44% 2.19% (13.58–14.69%) 19.17% 2.85% 21.45% 1.59%
Schizophrenia 2.43% 0.24% (1.89–2.39%) 1.43% 0.08% 8.76% 0.36%
IBD 0.83% 0.54% (0.13–0.43%) 0.68% 0.21% 1.99% 0.79%
Bowel disorders (not IBD) 11.74% 4.5% (5.72–6.68%) 11.63% 5.02% 12.97% 3.94%
DM1 0.79% 0.34% (0.3–0.6%) 0.67% 0.29% 2.08% 0.37%
Sleep Disorders 1.12% 0.14% (0.79–1.14%) 1.25% 0.2% 0.41% 0.1%
Autoimmune Disorders (not IBD,
not DM1)
0.67% 0.68% (20.14-0.13%) 0.51% 0.23% 0.53% 1.04%
Muscular Dystrophy 0.47% 0.05% 0.26–0.49% 0.49% 0.06% 0.42% 0.04%
Confidence interval shown is the 95
th for the difference in the proportions. The columns 2,3 describe the proportions for all ages, columns 4,5 ages 0–17 and columns
6,7 ages 18–34).
doi:10.1371/journal.pone.0033224.t002
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percent of patients with ASD having bowel disorders, or epilepsy,
over 5% with CNS or cranial anomalies, and over 2% with
schizophrenia. With regard to schizophrenia, although the 2%
prevalence was high relative to the general hospital population
study, there is a broader controversy of whether or not the
population prevalence is 5% or much lower [21,45].
This study also confirms the high prevalence of ASD in fragile
X syndrome, tuberous sclerosis and Down’s syndrome. Muscular
dystrophy, which mostly is constituted of genetically defined
diseases, also has a high prevalence of ASD. The prevalence of
ASD in individuals with the diagnosis of epilepsy or schizophrenia
in this population is similarly elevated.
Although several studies have previously pointed to an increased
prevalence of bowel disorders in individuals with autism/PDD,
with up to 25% with three or more gastrointestinal complaints/
disorders [1,5], others have suggested that the prevalence of 9% in
ASD is no larger than that of the general pediatric population
[39]. In this study, we found a significant enrichment of bowel
symptoms and disorders in patients with ASD (11.74% vs. 4.5%,
p,0.0001 by chi-square test) but these results may well be affected
by the limitations of our study, discussed above. Similarly, sleep
disorders have been documented in as many as 25% of all children
with ASD [13] but even though the prevalence of sleep disorders
in ASD in this study was almost ten times that of the general
hospital population, it was nonetheless, only 1.1.%
Of those co-morbidities found to have a higher prevalence than
that of the general hospital population studied, three increased
significantly with age. Two of them, IBD and DM1 have an
autoimmune component to their pathogenesis—a process that
large population studies have implicated at least in the risk for
ASD, and the third, schizophrenia has been found to have
considerable genetic overlap with the ASD population
[46,47,48,49].
In addition to the limitations outlined in the introduction, we
did not implement a master patient index across the four (often
competing) hospitals and therefore some patients may been
represented more than once by moving from one hospital to
another. Nonetheless, the pediatric hospital alone (ASD N=9105)
and the general hospitals alone (ASD N=5276), did not have this
problem individually and those comorbidities that were found to
be significantly enriched across all hospitals were also found in the
individual hospitals (data not shown).
These limitations noted above also point to future directions to
pursue these investigations. Although it is reassuring that we
replicated the approximate co-morbidities of ASD of several
diseases found in other studies, the differences with regard to some
prior studies do require additional explanation. Short of a
prospective study, retrospective studies can be undertaken either
with human chart review or by application of natural language
processing of the electronically stored clinical notes. Based on our
experience in other NLP-driven phenotyping efforts in major
depressive disorder, asthma, bipolar disorder, and rheumatoid
arthritis [26,38], this may be both a cost effective and accurate
mechanism for a deeper study. The problem of double counting
shared patients can and will be addressed by using established
mechanisms [50,51] for automatically matching patients even
while maintaining their anonymity.
The differences notwithstanding, this comorbidity topography
in four large hospitals presents an informative sketch of the burden
of ASD for healthcare system and families alike. It also suggests
that this spectrum disorder includes substantial use of specialty
clinics outside that of the developmental clinics/center and that
this burden increases with age.
Figure 3. Comorbidities of ASD in younger (0–17 years) vs older (18–34 years). All the comorbidities’ prevalence were significantly different
(p,0.0001 by Chi square) except for bowel disorders, epilepsy, autoimmune disorders (excluding IBD and DM1) and sleep disorders.
doi:10.1371/journal.pone.0033224.g003
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